350 related articles for article (PubMed ID: 31377458)
21. The detection of SRSF2 mutations in routinely processed bone marrow biopsies is useful in the diagnosis of chronic myelomonocytic leukemia.
Federmann B; Abele M; Rosero Cuesta DS; Vogel W; Boiocchi L; Kanz L; Quintanilla-Martinez L; Orazi A; Bonzheim I; Fend F
Hum Pathol; 2014 Dec; 45(12):2471-9. PubMed ID: 25305095
[TBL] [Abstract][Full Text] [Related]
22. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.
Kohlmann A; Grossmann V; Klein HU; Schindela S; Weiss T; Kazak B; Dicker F; Schnittger S; Dugas M; Kern W; Haferlach C; Haferlach T
J Clin Oncol; 2010 Aug; 28(24):3858-65. PubMed ID: 20644105
[TBL] [Abstract][Full Text] [Related]
23. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
[TBL] [Abstract][Full Text] [Related]
24. Genomic Landscape and Risk Stratification in Chronic Myelomonocytic Leukemia.
Hunter A; Padron E
Curr Hematol Malig Rep; 2021 Jun; 16(3):247-255. PubMed ID: 33660195
[TBL] [Abstract][Full Text] [Related]
25. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.
Smith AE; Mohamedali AM; Kulasekararaj A; Lim Z; Gäken J; Lea NC; Przychodzen B; Mian SA; Nasser EE; Shooter C; Westwood NB; Strupp C; Gattermann N; Maciejewski JP; Germing U; Mufti GJ
Blood; 2010 Nov; 116(19):3923-32. PubMed ID: 20693430
[TBL] [Abstract][Full Text] [Related]
26. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia.
Patnaik MM; Lasho TL; Vijayvargiya P; Finke CM; Hanson CA; Ketterling RP; Gangat N; Tefferi A
Blood Cancer J; 2016 Jan; 6(1):e385. PubMed ID: 26771811
[TBL] [Abstract][Full Text] [Related]
27. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML).
Meggendorfer M; Roller A; Haferlach T; Eder C; Dicker F; Grossmann V; Kohlmann A; Alpermann T; Yoshida K; Ogawa S; Koeffler HP; Kern W; Haferlach C; Schnittger S
Blood; 2012 Oct; 120(15):3080-8. PubMed ID: 22919025
[TBL] [Abstract][Full Text] [Related]
28. Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management.
Patnaik MM; Tefferi A
Am J Hematol; 2022 Mar; 97(3):352-372. PubMed ID: 34985762
[TBL] [Abstract][Full Text] [Related]
29. [Clinical Characteristics and Survival Analysis of Patients with Chronic Myelomonocytic Leukemia].
Wang JY; Chen JF; Wang SF; Guo QH; Ma YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):476-482. PubMed ID: 37096522
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: Clinical and Molecular Genetic Prognostic Factors in a Nordic Population.
Wedge E; Hansen JW; Dybedal I; Creignou M; Ejerblad E; Lorenz F; Werlenius O; Ungerstedt J; Holm MS; Nilsson L; Kittang AO; Antunovic P; Rohon P; Andersen MK; Papaemmanuil E; Bernard E; Jädersten M; Hellström-Lindberg E; Grønbæk K; Ljungman P; Friis LS
Transplant Cell Ther; 2021 Dec; 27(12):991.e1-991.e9. PubMed ID: 34500124
[TBL] [Abstract][Full Text] [Related]
31. Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis.
Hu Z; Ramos CEB; Medeiros LJ; Zhao C; Yin CC; Li S; Hu S; Wang W; Thakral B; Xu J; Verstovsek S; Lin P
Hum Pathol; 2019 Mar; 85():290-298. PubMed ID: 30447300
[TBL] [Abstract][Full Text] [Related]
32. How I diagnose and treat chronic myelomonocytic leukemia.
Patnaik MM
Haematologica; 2022 Jul; 107(7):1503-1517. PubMed ID: 35236051
[TBL] [Abstract][Full Text] [Related]
33. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia.
Kosmider O; Gelsi-Boyer V; Ciudad M; Racoeur C; Jooste V; Vey N; Quesnel B; Fenaux P; Bastie JN; Beyne-Rauzy O; Stamatoulas A; Dreyfus F; Ifrah N; de Botton S; Vainchenker W; Bernard OA; Birnbaum D; Fontenay M; Solary E;
Haematologica; 2009 Dec; 94(12):1676-81. PubMed ID: 19797729
[TBL] [Abstract][Full Text] [Related]
34. Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management.
Patnaik MM; Tefferi A
Am J Hematol; 2020 Jan; 95(1):97-115. PubMed ID: 31736132
[TBL] [Abstract][Full Text] [Related]
35. Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified.
Wang SA; Tam W; Tsai AG; Arber DA; Hasserjian RP; Geyer JT; George TI; Czuchlewski DR; Foucar K; Rogers HJ; Hsi ED; Bryan Rea B; Bagg A; Dal Cin P; Zhao C; Kelley TW; Verstovsek S; Bueso-Ramos C; Orazi A
Mod Pathol; 2016 Aug; 29(8):854-64. PubMed ID: 27174585
[TBL] [Abstract][Full Text] [Related]
36. When clinical heterogeneity exceeds genetic heterogeneity: thinking outside the genomic box in chronic myelomonocytic leukemia.
Ball M; List AF; Padron E
Blood; 2016 Nov; 128(20):2381-2387. PubMed ID: 27707735
[TBL] [Abstract][Full Text] [Related]
37. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.
Gelsi-Boyer V; Trouplin V; Roquain J; Adélaïde J; Carbuccia N; Esterni B; Finetti P; Murati A; Arnoulet C; Zerazhi H; Fezoui H; Tadrist Z; Nezri M; Chaffanet M; Mozziconacci MJ; Vey N; Birnbaum D
Br J Haematol; 2010 Nov; 151(4):365-75. PubMed ID: 20880116
[TBL] [Abstract][Full Text] [Related]
38. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia.
Elena C; Gallì A; Such E; Meggendorfer M; Germing U; Rizzo E; Cervera J; Molteni E; Fasan A; Schuler E; Ambaglio I; Lopez-Pavia M; Zibellini S; Kuendgen A; Travaglino E; Sancho-Tello R; Catricalà S; Vicente AI; Haferlach T; Haferlach C; Sanz GF; Malcovati L; Cazzola M
Blood; 2016 Sep; 128(10):1408-17. PubMed ID: 27385790
[TBL] [Abstract][Full Text] [Related]
39. Cytogenetic clonality in chronic myelomonocytic leukemia studied with fluorescence in situ hybridization.
Fugazza G; Bruzzone R; Dejana AM; Gobbi M; Ghio R; Patrone F; Rattenni S; Sessarego M
Leukemia; 1995 Jan; 9(1):109-14. PubMed ID: 7845004
[TBL] [Abstract][Full Text] [Related]
40. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.
Jankowska AM; Makishima H; Tiu RV; Szpurka H; Huang Y; Traina F; Visconte V; Sugimoto Y; Prince C; O'Keefe C; Hsi ED; List A; Sekeres MA; Rao A; McDevitt MA; Maciejewski JP
Blood; 2011 Oct; 118(14):3932-41. PubMed ID: 21828135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
